Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Gevo, Inc.

GEVO Nasdaq Industrial Organic Chemicals Financials FY2016–FY2025

Gevo, Inc. had $161M of revenue in fiscal 2025, up 849.3% on the year before. Over five years, revenue changed +96.1% a year on average.

Add to portfolio Download report

Last close Β· Oct 23, 2026

$1.16

1.8%

What Gevo, Inc. does

GEVO Β· Industrial Organic Chemicals

From its latest annual report

No business description yet.

Filing details

Legal name
Gevo, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 5, 2026
Accession Β· CIK
0001392380-26-000006 Β· 0001392380

Earnings calendar Β· Gevo, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Gevo, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 9, 2026

Monday Β· in 13 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
$0.04
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 6, 2026 Q2 '26 After the market closes 8-K β†—
May 7, 2026 Q1 '26 After the market closes 8-K β†—
Mar 5, 2026 Q4 '25 After the market closes 8-K β†—
Nov 10, 2025 Q3 '25 After the market closes 8-K β†—
Aug 11, 2025 Q2 '25 After the market closes 8-K β†—
May 13, 2025 Q1 '25 After the market closes 8-K β†—
Mar 27, 2025 Q4 '24 After the market closes 8-K β†—
Nov 7, 2024 Q3 '24 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Gevo, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

1 strength 6 to watch

1.Sales and profit

See section β†’
  • Gevo, Inc. had $161M of revenue in fiscal 2025, up 849.3% on the year before. Over five years, revenue changed +96.1% a year on average.
  • Its operating margin was βˆ’12.6%, up 524.4Β pts: of every 100 in sales, about βˆ’13 is left after running the business.
  • Gevo, Inc. lost $33.8M in fiscal 2025.

3.Financial health

See section β†’
  • Gevo, Inc. owes $84.3M more than it holds in cash, about 16.5 years of operating profit.
  • Its return on capital was βˆ’2.9%: every 100 invested in the business earned about βˆ’3 in a year.
  • Gevo, Inc. passes 3 of 8 financial health tests (Piotroski F-score).

Gevo, Inc. in 30 seconds

Good So-so Weak

Good

Are sales growing?

+849.3%

Yes. Sales grew 849.3% last year.

Weak

Does it make a profit?

βˆ’21.1%

No. It lost money last year.

Weak

Does profit turn into cash?

βˆ’27.1%

No. It spent more cash than it brought in.

Weak

Is debt under control?

16.5x

Heavy. Repaying its debt would take 16.5 years of operating profit.

Weak

How healthy are the accounts?

3 / 8

Weak. It passes 3 of 8 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$275M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$0.90 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Gevo, Inc. had $161M of revenue in fiscal 2025, up 849.3% on the year before. Over five years, revenue changed +96.1% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was βˆ’12.6%, up 524.4Β pts: of every 100 in sales, about βˆ’13 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Gevo, Inc. lost $33.8M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$43.5M in fiscal 2025, βˆ’27.1% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

KIRA Β· Its return on capital was βˆ’2.9%: every 100 invested in the business earned about βˆ’3 in a year.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Gevo, Inc. had $161M of revenue in fiscal 2025, up 849.3% on the year before. Over five years, revenue changed +96.1% a year on average. Its operating margin was βˆ’12.6%, up 524.4Β pts: of every 100 in sales, about βˆ’13 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Gevo, Inc. lost $33.8M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$43.5M in fiscal 2025, βˆ’27.1% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders bought $0.1M and sold $2.8M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.1M

2 insiders

Sold, 12 months

$2.8M

10 insiders

Of sales under plans

80%

$2.3M

DateInsiderTradeSharesPriceValueFiling
Sep 3, 2026 Paul D BloomCEO, Director Sold plan 1,514 $1.71 $0.0M Form 4
Sep 3, 2026 Patrick R. GruberDirector Sold plan 3,333 $1.70 $0.0M Form 4
Sep 3, 2026 Kimberly T BowronChief of Staff Sold plan 1,221 $1.71 $0.0M Form 4
Aug 21, 2026 David Michael KettnerChief Legal & Emrg Biz Officer Bought 12,500 $1.55 $0.0M Form 4
Aug 21, 2026 James J BarberDirector Bought 50,000 $1.54 $0.1M Form 4
Aug 6, 2026 Paul D BloomCEO, Director Sold plan 31,096 $1.55 $0.0M Form 4
Aug 6, 2026 Kimberly T BowronChief of Staff Sold plan 10,257 $1.55 $0.0M Form 4
Aug 6, 2026 Oluwagbemileke Yusuf AgiriCFO Sold plan 18,223 $1.54 $0.0M Form 4
Aug 6, 2026 Patrick R. GruberDirector Sold plan 247,642 $1.51 $0.4M Form 4
Jun 12, 2026 Kimberly T BowronChief of Staff Sold plan 15,470 $1.43 $0.0M Form 4
Jun 12, 2026 Oluwagbemileke Yusuf AgiriCFO Sold plan 63,028 $1.40 $0.1M Form 4
Jun 12, 2026 Davaajargal GendenjamtsVP Acctg and Treasurer Sold plan 4,293 $1.43 $0.0M Form 4
Jun 12, 2026 Christopher Michael RyanPresident & COO Sold plan 35,196 $1.43 $0.1M Form 4
Jun 12, 2026 Patrick R. GruberDirector Sold plan 157,563 $1.40 $0.2M Form 4
Jun 12, 2026 Paul D BloomCEO, Director Sold plan 35,189 $1.43 $0.1M Form 4
Jun 12, 2026 Andrew ShaferChief Mktg Cust & Brnd Officer Sold plan 9,443 $1.43 $0.0M Form 4
May 27, 2026 Patrick R. GruberDirector Sold plan 186,469 $1.76 $0.3M Form 4
May 27, 2026 Christopher Michael RyanPresident & COO Sold plan 87,700 $1.76 $0.2M Form 4
May 27, 2026 Paul D BloomCEO, Director Sold plan 75,735 $1.76 $0.1M Form 4
May 27, 2026 Andrew ShaferChief Mktg Cust & Brnd Officer Sold plan 32,667 $1.76 $0.1M Form 4
May 27, 2026 Oluwagbemileke Yusuf AgiriCFO Sold plan 31,958 $1.77 $0.1M Form 4
May 27, 2026 Kimberly T BowronChief of Staff Sold plan 25,101 $1.76 $0.0M Form 4
May 1, 2026 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,550 $2.00 $0.0M Form 4
Apr 1, 2026 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,550 $2.71 $0.0M Form 4
Mar 31, 2026 Christopher Michael RyanPresident & COO Sold plan 29,797 $2.96 $0.1M Form 4
Mar 30, 2026 Christopher Michael RyanPresident & COO Sold plan 100,000 $2.76 $0.3M Form 4
Mar 12, 2026 Lindsay Clinton FitzgeraldChief Public Affairs Officer Sold plan 20,000 $2.51 $0.1M Form 4
Mar 12, 2026 Gary W. MizeDirector Sold 107,100 $2.34 $0.3M Form 4
Mar 10, 2026 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,550 $2.21 $0.0M Form 4
Jan 20, 2026 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,000 $1.99 $0.0M Form 4
Dec 22, 2025 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,000 $2.19 $0.0M Form 4
Dec 5, 2025 Oluwagbemileke Yusuf AgiriCFO Sold 73,284 $2.31 $0.2M Form 4
Dec 4, 2025 Davaajargal GendenjamtsVP Acctg and Treasurer Sold 2,560 $2.32 $0.0M Form 4
Nov 20, 2025 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,000 $1.99 $0.0M Form 4
Nov 13, 2025 Carol Jane BattershellDirector Sold 75,597 $2.02 $0.2M Form 4
Nov 3, 2025 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 29,797 $2.28 $0.1M Form 4
Oct 20, 2025 Andrew ShaferChief Cust Mkt & Brnd Officer Sold plan 5,000 $2.53 $0.0M Form 4
Oct 15, 2025 Christopher Michael RyanPresident & COO Sold plan 100,000 $2.82 $0.3M Form 4
Oct 14, 2025 Angelo AmorelliDirector Sold plan 100,000 $2.50 $0.3M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Gevo, Inc. owes $84.3M more than it holds in cash, about 16.5 years of operating profit.

Cash, debt and the ratios that show how comfortably Gevo, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $316M$405M$298M$189M$81.2M
Debt incl. finance leases $88.2M$67.8M$68.4M$69.3M$165M
Net debt / EBITDA β€”β€”β€”β€”16.5x
Debt / equity 0.1x0.1x0.1x0.1x0.4x
Interest coverage βˆ’240.1xβˆ’88.0xβˆ’37.9xβˆ’23.4xβˆ’1.2x
Current ratio 12.0x16.3x4.2x8.4x1.8x
Quick ratio 11.9x16.1x4.2x8.2x1.6x
Total assets $645M$701M$650M$584M$719M
Total liabilities $98.1M$95.3M$92.9M$94.5M$248M
Shareholders' equity $547M$605M$557M$489M$466M
Net debt (βˆ’ = net cash) βˆ’$228Mβˆ’$337Mβˆ’$230Mβˆ’$120M$84.3M

Returns on capital

KIRA Β· Its return on capital was βˆ’2.9%: every 100 invested in the business earned about βˆ’3 in a year.

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Gevo, Inc. passes 3 of 8 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ“ βœ• βœ“ βœ“ βœ• βœ“ βœ• βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” βœ• βœ• βœ“ βœ• βœ• βœ•
Current ratio rose β€” βœ“ βœ“ βœ• βœ“ βœ• βœ“ βœ• βœ“ βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ“ βœ•
Gross margin rose β€” βœ• βœ“ βœ• βœ• βœ• β€” β€” β€” β€”
Revenue rose relative to assets β€” βœ“ βœ• βœ• βœ• βœ• βœ“ βœ“ βœ“ βœ“
F-score β€” / 34 / 84 / 81 / 83 / 92 / 94 / 83 / 84 / 83 / 8
Accruals ratio βˆ’14.9%βˆ’4.0%βˆ’12.4%βˆ’7.8%βˆ’17.0%βˆ’2.7%βˆ’8.0%βˆ’1.8%βˆ’3.4%βˆ’3.1%
Altman Z'' βˆ’10.76βˆ’13.37βˆ’7.31βˆ’13.9518.385.666.294.811.94βˆ’1.40

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $27.2M $27.5M $32.9M $24.5M $5.5M $0.7M $1.2M $17.2M $16.9M $161M
Gross profit βˆ’$9.8M βˆ’$10.6M βˆ’$8.7M βˆ’$12.2M βˆ’$9.5M βˆ’$11.5M β€” β€” β€” β€”
Research and development $5.2M $5.2M $5.4M $3.9M $3.5M $6.8M $7.4M $6.6M $5.6M $4.6M
Operating income βˆ’$24.0M βˆ’$23.3M βˆ’$22.2M βˆ’$26.4M βˆ’$27.0M βˆ’$60.3M βˆ’$103M βˆ’$81.8M βˆ’$90.8M βˆ’$20.2M
Interest expense $7.8M $3.0M $3.2M $2.7M $2.1M $0.3M $1.2M $2.2M $3.9M $17.6M
Pretax income β€” β€” β€” β€” β€” β€” β€” β€” βˆ’$78.6M βˆ’$32.6M
Income tax β€” β€” $0.0M $0.0M $0.0M β€” β€” β€” β€” β€”
Net income βˆ’$37.2M βˆ’$24.6M βˆ’$28.0M βˆ’$28.7M βˆ’$40.2M βˆ’$59.2M βˆ’$98.0M βˆ’$66.2M βˆ’$78.6M βˆ’$33.8M
Net income to common β€” β€” β€” β€” β€” βˆ’$59.2M βˆ’$98.0M βˆ’$66.2M βˆ’$78.6M β€”
Diluted EPS βˆ’$193.52 βˆ’$30.23 βˆ’$5.74 βˆ’$2.35 βˆ’$0.71 βˆ’$0.30 βˆ’$0.44 βˆ’$0.28 βˆ’$0.34 βˆ’$0.14
Diluted shares 0.00B 0.00B 0.00B 0.01B 0.06B 0.20B 0.22B 0.24B 0.23B 0.23B
Cash flow
Cash from operations βˆ’$20.5M βˆ’$20.6M βˆ’$15.9M βˆ’$20.8M βˆ’$19.3M βˆ’$48.3M βˆ’$44.3M βˆ’$53.7M βˆ’$57.4M βˆ’$13.4M
Capital expenditure $5.9M $1.9M $2.2M $6.5M $6.2M $56.8M $84.1M $54.5M $51.1M $30.1M
Free cash flow βˆ’$26.5M βˆ’$22.5M βˆ’$18.1M βˆ’$27.3M βˆ’$25.6M βˆ’$105M βˆ’$128M βˆ’$108M βˆ’$108M βˆ’$43.5M
Depreciation and amortization $6.7M $6.6M $6.5M $6.7M $5.9M $5.1M $7.9M $19.0M $18.3M $25.3M
Stock-based compensation $0.9M $0.4M $0.7M $1.3M $2.1M $9.9M $17.4M $17.1M $14.7M $9.2M
Acquisitions β€” β€” β€” β€” β€” β€” β€” β€” $6.1M β€”
Share buybacks β€” β€” β€” β€” β€” β€” β€” β€” $4.7M β€”
Dividends and buybacks β€” β€” β€” β€” β€” β€” β€” β€” $4.7M β€”
Balance sheet
Cash and short-term investments $27.9M $11.6M $33.7M $16.3M $78.3M $316M $405M $298M $189M $81.2M
Total debt $35.7M β€” β€” $0.7M $1.3M $67.0M $67.5M $68.1M $67.1M $165M
Finance lease liabilities β€” β€” β€” β€” $0.2M $21.2M $0.3M $0.2M $2.2M $0.7M
Current assets $33.3M $17.7M $38.7M $24.2M $83.3M $349M $415M $386M $204M $143M
Current liabilities $34.7M $11.2M $5.3M $20.1M $4.9M $29.1M $25.4M $91.4M $24.4M $78.6M
Inventory $3.5M $4.4M $3.2M $3.2M $2.5M $2.8M $6.3M $3.8M $4.5M $19.1M
Property and equipment, net $75.6M $70.4M $67.5M $66.7M $66.4M $138M $185M $212M $222M $354M
Goodwill β€” β€” β€” β€” β€” β€” β€” β€” $3.7M $43.6M
Intangible assets β€” β€” β€” β€” $0.1M $8.9M $7.7M $6.5M $8.1M $95.0M
Total assets $112M $88.9M $107M $93.4M $152M $645M $701M $650M $584M $719M
Total liabilities $43.1M $25.3M $18.2M $20.9M $5.7M $98.1M $95.3M $92.9M $94.5M $248M
Shareholders' equity $69.3M $63.5M $88.8M $72.5M $146M $547M $605M $557M $489M $466M
Margins
Gross margin βˆ’36.0% βˆ’38.6% βˆ’26.5% βˆ’50.0% βˆ’171.0% βˆ’1,611.0% β€” β€” β€” β€”
Operating margin βˆ’88.1% βˆ’84.6% βˆ’67.6% βˆ’107.6% βˆ’487.0% βˆ’8,476.5% βˆ’8,739.2% βˆ’475.8% βˆ’536.9% βˆ’12.6%
EBITDA margin βˆ’63.3% βˆ’60.4% βˆ’47.7% βˆ’80.4% βˆ’380.4% βˆ’7,755.3% βˆ’8,068.0% βˆ’365.3% βˆ’428.8% 3.2%
Net margin βˆ’136.8% βˆ’89.4% βˆ’85.1% βˆ’117.0% βˆ’725.9% βˆ’8,326.7% βˆ’8,341.0% βˆ’385.0% βˆ’464.9% βˆ’21.1%
FCF margin βˆ’97.2% βˆ’81.8% βˆ’55.0% βˆ’111.6% βˆ’461.6% βˆ’14,773.7% βˆ’10,926.6% βˆ’628.9% βˆ’641.3% βˆ’27.1%
Returns
Return on capital βˆ’24.6% β€” β€” βˆ’36.6% βˆ’30.7% βˆ’16.0% βˆ’30.2% βˆ’19.8% βˆ’19.5% βˆ’2.9%
Return on capital employed βˆ’30.9% βˆ’30.0% βˆ’21.8% βˆ’36.0% βˆ’18.3% βˆ’9.8% βˆ’15.2% βˆ’14.6% βˆ’16.2% βˆ’3.2%
Return on equity βˆ’53.7% βˆ’37.1% βˆ’36.7% βˆ’35.5% βˆ’36.7% βˆ’17.1% βˆ’17.0% βˆ’11.4% βˆ’15.0% βˆ’7.1%
Return on assets βˆ’33.1% βˆ’24.5% βˆ’28.6% βˆ’28.6% βˆ’32.7% βˆ’14.8% βˆ’14.6% βˆ’9.8% βˆ’12.7% βˆ’5.2%
Return on tangible equity βˆ’53.7% βˆ’38.8% βˆ’31.5% βˆ’39.5% βˆ’27.5% βˆ’11.0% βˆ’16.4% βˆ’12.0% βˆ’16.5% βˆ’10.3%
Growth
Revenue growth β€” 1.2% 19.3% βˆ’25.5% βˆ’77.4% βˆ’87.2% 65.3% 1,363.8% βˆ’1.7% 849.3%
Share count change β€” 323.5% 498.5% 149.7% 367.1% 244.2% 13.1% 7.7% βˆ’2.9% 1.0%
Financial health
Net debt / EBITDA β€” β€” β€” β€” β€” β€” β€” β€” β€” 16.5x
Debt / equity 0.5x β€” β€” 0.0x 0.0x 0.1x 0.1x 0.1x 0.1x 0.4x
Interest coverage βˆ’3.1x βˆ’7.9x βˆ’6.9x βˆ’9.6x βˆ’12.9x βˆ’240.1x βˆ’88.0x βˆ’37.9x βˆ’23.4x βˆ’1.2x
Current ratio 1.0x 1.6x 7.3x 1.2x 16.9x 12.0x 16.3x 4.2x 8.4x 1.8x
Quick ratio 0.9x 1.2x 6.7x 1.0x 16.4x 11.9x 16.1x 4.2x 8.2x 1.6x
Capital allocation
Capex / revenue 21.8% 6.9% 6.8% 26.5% 112.3% 7,984.5% 7,155.5% 316.6% 302.0% 18.8%
Stock comp / revenue 3.3% 1.5% 2.1% 5.5% 38.4% 1,388.7% 1,482.5% 99.3% 87.1% 5.7%
Quality scores
Piotroski F-score β€” 4.0 4.0 1.0 3.0 2.0 4.0 3.0 4.0 3.0
Altman Z'' βˆ’10.8 βˆ’13.4 βˆ’7.3 βˆ’13.9 18.4 5.7 6.3 4.8 1.9 βˆ’1.4
Accruals ratio βˆ’14.9% βˆ’4.0% βˆ’12.4% βˆ’7.8% βˆ’17.0% βˆ’2.7% βˆ’8.0% βˆ’1.8% βˆ’3.4% βˆ’3.1%

Source: SEC EDGAR XBRL filings (CIK 0001392380). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open